Search

Your search keyword '"Attanagoda S"' showing total 2 results
Start Over Author "Attanagoda S"
2 results on '"Attanagoda S"'

1. Monitor and control systems for the SLD Cherenkov ring-imaging detector

Author

Antilogus, P., primary, Aston, D., additional, Bienz, T., additional, Bird, F., additional, Dasu, S., additional, Dunwoodie, W., additional, Fernandez, F., additional, Hallewell, G., additional, Kawahara, H., additional, Korff, P., additional, Kwon, Y., additional, Leith, D., additional, Muller, D., additional, Nagamine, T., additional, Pavel, T., additional, Rabinowitz, L., additional, Ratcliff, B., additional, Rensing, P., additional, Schultz, D., additional, Shapiro, S., additional, Simopoulos, C., additional, Solodov, E., additional, Toge, N., additional, Va'vra, J., additional, Williams, S., additional, Whitaker, J., additional, Wilson, R.J., additional, Bean, A., additional, Caldwell, D., additional, Duboscq, J., additional, Huber, J., additional, Lu, A., additional, McHugh, S., additional, Mathys, L., additional, Morrison, R., additional, Witherell, M., additional, Yellin, S., additional, Cavalli-Sforza, M., additional, Coyle, P., additional, Coyne, D., additional, Gagnon, P., additional, Williams, D.A., additional, Zucchelli, P., additional, Attanagoda, S., additional, Johnson, R., additional, Martinez, J., additional, Meadows, B., additional, Nussbaum, M., additional, Shoup, A., additional, Sokoloff, M., additional, Stockdale, I., additional, Plano, R., additional, Jacques, P., additional, Stamer, P., additional, Abe, K., additional, Hasegawa, K., additional, Suekane, F., additional, and Yuta, H., additional

Published
1990
Full Text
View/download PDF

2. A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole.

Author

Springer C, Rodgers R, Vivino G, Attanagoda S, and Miks CD

Subjects
Female, Humans, Adult, Cabergoline, Aripiprazole adverse effects, Delusions, Ergolines adverse effects, Dopamine Agonists adverse effects, Prolactinoma drug therapy, Pituitary Neoplasms drug therapy
Abstract

Abstract: Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of aripiprazole to mitigate the psychotic symptoms, while maintaining the efficacy of cabergoline treatment., Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results